The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.
MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company said ...
Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...
The Badger Project on MSN15d
FINAL REPORT: Top donors to Rebecca Cooke, Democrat of western WisconsinRunning her second campaign for Congress, Rebecca Cooke has raised more than $5.3 million through the final reporting period, ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test ...
Daniel Brennan, an analyst from TD Cowen, reiterated the Buy rating on Exact Sciences (EXAS – Research Report). The associated price ...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a ...
The webcast can be accessed in the investor relations section of Exact Sciences’ website at About Exact Sciences Corp. A leading provider of cancer screen ...
Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based company said it had a loss of 21 cents.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback